I'll research GL (Globe Life Inc.) to build a well-grounded earnings preview. Let me gather recent filings, transcripts, and news.Let me read the most recent earnings materials and the year-ago Q2 for comparison.Let me get the year-ago Q2 release for comparison, plus recent news and stock price data.I have strong fundamental data. Let me check the recent 8-K on refinancing and search for analyst consensus and any outstanding overhangs (DOJ/SEC inquiry, Bermuda).Let me retry the web search with correct parsing and check the DOJ/SEC investigation status.I have enough to write a well-grounded preview. Let me compile the key numbers.Here is my earnings preview.
Report date: After close Wed, July 22, 2026 · Call: 11:00 a.m. ET Thu, July 23, 2026 Recent price: ~$184 · Setup: Stock +33% YTD and +22% since the Q1 print, sitting near all-time highs into the report
GL enters this print with strong operating momentum (double-digit operating EPS growth in 7 of the last 8 quarters), a raised full-year guide, an accelerating health/Medicare-Supplement story, and a very rich stock. The bar has moved up meaningfully — this is now an "execution + no negative surprises" quarter, with the real numbers catalyst (the Q3 assumption update) and the Bermuda capital update as the two forward items that matter most.
1. American Income Life (AIL) agent-count inflection — the key debate. AIL is the profit engine, and its average producing agent count fell to 11,064 in Q1 2026, down 4% YoY (year-ago Q2 base was 12,241), driven by weaker new-agent retention. Management said it implemented middle-management comp changes at the start of Q2 to re-weight toward recruiting/retention, and expects agent-count growth to show up in the second half. Q2 is the first read on whether that pendulum is swinging back. Full-year guide: AIL low-single-digit agent growth and mid-single-digit life-sales growth. Productivity has been the offset (life sales grew even as heads fell) — watch whether that holds.
2. United American / Medicare Supplement — the growth surprise. This has been the standout. UA health net sales more than doubled in Q1 (to ~$62M) on the Medicare Advantage → Medicare Supplement migration, and management guided full-year UA sales to high-teens growth on top of a huge 2025. Two things to track: - Sales durability: management flagged tougher comps building through the year (Q4 laps a near-doubling), so decelerating growth off a high base is expected, not a red flag. - Margin recovery: UA margin was thin (Q1 ~3%; year-ago Q2 was 8%), but ~$65M of approved individual Med-Supp rate increases flow in mostly across Q2–Q4 (~$20M/quarter). Management expects UA margin ~10% over the final three quarters, lifting the total health margin above 25% in Q2 (vs. 23% in Q1; 26% year-ago). Health premium growth guided at 14–17% for the year.
3. The Q3 assumption update — the real numbers catalyst is next quarter, but it gets pre-marketed here. GL updates life/health assumptions annually in Q3. Management has guided a pre-tax benefit of $70–110M (≈$0.70–$1.10/sh after tax) and a Q3 life margin of 49–54% vs. the ~41% normalized run-rate. On this call, watch for any refinement to that range and, more importantly, commentary on whether favorable mortality trends persist (heart/circulatory, non-lung cancer, and notably improving non-medical deaths — suicide/overdose). Persistent good mortality is what resets the long-term margin higher, so the qualitative mortality read-through matters more than the one-time gain.
4. Bermuda / capital — management pre-committed to a "more significant update" this call. On the Q1 call, management said it would file for reciprocal jurisdiction in Q2 and provide a fuller update next quarter. Guidance currently assumes no incremental parent cash flow from the new Bermuda entity, so any framing of future reinsurance cessions or added capital generation is potential upside not yet in numbers. Related housekeeping: in late June GL refinanced its credit facilities and upsized its term loan from $250M to $450M (extended maturities to 2029/2031) — a modest capital-structure positive.
5. Capital return pace. GL bought back $203M in Q1 (1.4M shares at ~$141) — accelerated to take advantage of a dip below $140. Full-year buyback guide was raised to $560–610M, on excess cash flow narrowed to $650–700M, plus a 22% dividend increase. The question into H2: with the stock now ~$184 (vs. ~$141 average repurchase price in Q1), does management stay disciplined on price, and does the higher share price slow the buyback cadence? Diluted share count is already down sharply YoY (79.7M in Q1'26 vs. 82.8M in Q2'25).
At ~$184, GL trades at roughly 11.8x the midpoint of 2026 operating EPS guidance and ~1.9x book value per share ex-AOCI ($98.56, +12% YoY at Q1). GAAP book value per share was $77.03 (+19% YoY), with ROE of 17.9% (14.0% ex-AOCI). Those are solid returns, but the ~33% YTD move means expectations — and downside sensitivity to any disappointment on AIL agent count, health margins, or the Bermuda update — are elevated going in.
| Metric | Year-ago (Q2'25) | What to look for |
|---|---|---|
| Net operating EPS | $3.27 | ~$3.60–3.75 (≈+11–14%) |
| Life underwriting margin % | 41% | ~41% (Q3 is the big-margin quarter) |
| Health underwriting margin % | 26% | >25% as rate increases flow in |
| AIL avg. producing agents | 12,241 | Sequential vs. 11,064 (Q1) — inflection? |
| UA health net sales | $25M | Growth off Q1's ~$62M surge |
| Buyback $ | $226M | Pace vs. $560–610M FY guide at higher price |
| FY2026 op EPS guide | (raised to) $15.40–$15.90 | Any further raise |
Sources: GL Q1 2026 earnings release and conference call (Apr 22–23, 2026), Q2 2025 earnings release (Jul 23, 2025), GL 8-K on credit facility refinancing (filed June 29, 2026), and market price data through July 21, 2026. EPS growth ranges and consensus framing are my own estimates derived from company guidance, not live sell-side consensus, which I was unable to retrieve.
Would you like me to pull the AIL/Liberty/Family Heritage division-level trends into a fuller model, or dig into the Q1 2026 10-Q for balance-sheet/reserve detail ahead of the print?